Document is current
Any future updates will be listed below
-
Authors
Mueller, Simon
Sachdeva, Bhuvan
Prasad, Singri Niharika
Lechtenboehmer, Raphael
Holz, Frank G
Finger, Robert P
Murali, Kaushik
Jain, Mohit
Wintergerst, Maximilian W M
Schultz, Thomas
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 27 September 2024
Accepted: 28 April 2025
First Online: 21 May 2025
Declarations
:
: Simon Müller: None; Bhuvan Sachdeva Microsoft: Research India; Singri Niharika Prasad: None; Raphael Lechtenboehmer: Grants: Deutsche Ophthalmologische Gesellschaft, Platenstr. 1 80336 München; Travel: Théa Pharma GmbH, Schillerstraße 3, 10625, Berlin; Frank G. Holz: Research Grant Support: Acucela, Allergan, Apellis, Bayer, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Kanghong, NightStarx, Novartis, Optos, Zeiss; Consultant: Acucela, Aerie, Allergan, Apellis, Bayer, Boehringer-Ingelheim, ivericbio, Roche/Genentech, Geuder, Grayburg Vision, ivericbio, LinBioscience, Kanghong, Novartis, Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss; Robert P. Finger: Consultant: Alimera, Apellis, Astellas, Bayer, Boehringer Ingelheim, Chiesi, OD-OS, Opthea, ProQR, Roche/Genentech Inc., Santen; Grant Support: Bayer, Biogen. Speaker: Alimera, Apellis, Bayer, Novartis, Roche; Kaushik Murali: None; Mohit Jain: Microsoft Research India; Maximilian W. M. Wintergerst: ASKIN & CO GmbH (R), Baxter Healthcare Corporation (F), Bayer AG (R), Berlin-Chemie AG (R, F), CenterVue SpA (F), Carl Zeiss Meditec (F), D-Eye Srl (F), DigiSight Technologies (R, F), Eyenuk, Inc. (F), Eyepress Fachmedien GmbH (R), glaucare GmbH (O, C), Heine Optotechnik GmbH (C, R, F), Heidelberg Engineering (R, F), Novartis Pharma GmbH (R, F), Optos (F), Pro Generika e.V. (R), Science Consulting in Diabetes GmbH (R); Thomas Schultz: None.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
